机构:[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[2]Cell Therapy Center, Xuanwu Hospital, The Capital Medical University, Beijing, China首都医科大学宣武医院[3]Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China[4]Department of Neurosurgery, Xuanwu Hospital, the Capital Medical University, Beijing, China神经科系统神经外科首都医科大学宣武医院[5]Beijing Neurosurgical Institute, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院
IntroductionGliomas are the most common primary brain tumors in adults and a significant cause of cancer-related mortality. A 9-gene signature was identified as a novel prognostic model reflecting survival situation obviously in gliomas. AimsTo identify an mRNA expression signature to improve outcome prediction for patients with different glioma grades. ResultsWe used whole-genome mRNA expression microarray data of 220 glioma samples of all grades from the Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn) as a discovery set and data from Rembrandt and GSE16011 for validation sets. Data from every single grade were analyzed by the Kaplan-Meier method with a two-sided log-rank test. Univariate Cox regression and linear risk score formula were applied to derive a gene signature with better prognostic performance. We found that patients who had high risk score according to the signature had poor overall survival compared with patients who had low risk score. Highly expressed genes in the high-risk group were analyzed by gene ontology (GO) and gene set variation analysis (GSVA). As a result, the reason for the divisibility of gliomas was likely due to cell life processes and adhesion. ConclusionThis 9-gene-signature prediction model provided a more accurate predictor of prognosis that denoted patients with high risk score have poor outcome. Moreover, these risk models based on defined molecular profiles showed the considerable prospect in personalized cancer management.
基金:
National High Technology Research and Development Program (No. 2012AA02A508)
International Science and Technology Cooperation Program (No. 2012DFA30470)
National Natural Science Foundation of China (No. 91229121, 81272804, 81071011)
第一作者机构:[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
通讯作者:
通讯机构:[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[4]Department of Neurosurgery, Xuanwu Hospital, the Capital Medical University, Beijing, China[5]Beijing Neurosurgical Institute, Beijing, China[*1]Beijing Neurosurgical Institute, No.6, Tiantan Xili, Dongcheng District, Beijing 100050, China.[*2]Department of Neurosurgery, Xuanwu Hospital, the Capital Medical University, No.45, Changchun Street, Xicheng District, Beijing 100053, China.
推荐引用方式(GB/T 7714):
Zhao-Shi Bao,Ming-Yang Li,Jia-Yin Wang,et al.Prognostic Value of a Nine-Gene Signature in Glioma Patients Based on mRNA Expression Profiling[J].CNS NEUROSCIENCE & THERAPEUTICS.2014,20(2):112-118.doi:10.1111/cns.12171.
APA:
Zhao-Shi Bao,Ming-Yang Li,Jia-Yin Wang,Chuan-Bao Zhang,Hong-Jun Wang...&Tao Jiang.(2014).Prognostic Value of a Nine-Gene Signature in Glioma Patients Based on mRNA Expression Profiling.CNS NEUROSCIENCE & THERAPEUTICS,20,(2)
MLA:
Zhao-Shi Bao,et al."Prognostic Value of a Nine-Gene Signature in Glioma Patients Based on mRNA Expression Profiling".CNS NEUROSCIENCE & THERAPEUTICS 20..2(2014):112-118